Related Experiment Video

Updated: Jun 10, 2026

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

11beta-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of type 2 diabetes

Stuart A Morgan1, Jeremy W Tomlinson

  • 1University of Birmingham, Centre for Endocrinology, Diabetes & Metabolism, Institute of Biomedical Research, School of Clinical and Experimental Medicine, 2nd floor, Room 230, Birmingham B15 2TH, UK.

Expert Opinion on Investigational Drugs
|August 17, 2010
PubMed
Abstract

Insights

Selective 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors show promise for treating obesity and type 2 diabetes by improving insulin sensitivity. Further clinical studies are needed to confirm their therapeutic potential.

Area of Science:

  • Metabolic disease research
  • Pharmacology
  • Endocrinology

Background:

  • Rising global prevalence of obesity and type 2 diabetes necessitates new therapeutic targets.
  • 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) is a key enzyme in metabolic regulation, implicated in obesity and diabetes.
  • Targeting 11beta-HSD1 offers a novel approach to managing metabolic syndrome.

Purpose of the Study:

  • To review the development of selective 11beta-HSD1 inhibitors.
  • To summarize preclinical evidence supporting 11beta-HSD1 as a therapeutic target.
  • To present the current status of clinical trials for 11beta-HSD1 inhibitors.

Main Methods:

  • Comprehensive literature review of preclinical and clinical studies.
  • Analysis of the role of 11beta-HSD1 in metabolic pathogenesis.
  • Evaluation of data from ongoing clinical trials.

Main Results:

  • Selective 11beta-HSD1 inhibitors reduce local glucocorticoid activity.
  • Preclinical data strongly support 11beta-HSD1 inhibition for metabolic improvement.
  • Early clinical studies indicate therapeutic potential, including improved insulin sensitivity and glucose tolerance.

Conclusions:

  • Selective 11beta-HSD1 inhibitors represent a promising therapeutic strategy for type 2 diabetes.
  • These inhibitors may improve insulin sensitivity, glucose control, and lipid profiles.
  • Further extensive clinical investigation is essential to establish the efficacy and safety of 11beta-HSD1 inhibitors.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...